ACET - CIK 0001720580
The table below shows Adicet Bio, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$95.25M | -$92.38M | -$93.72M | -$44.77M | -$51.05M | -$41.55M |
| Capital expenditure | $1.74M | $1.12M | $4.46M | $16.78M | $13.05M | $990.00K |
| Investing cash flow | $2.39M | -$119.24M | -$4.46M | -$16.78M | -$2.80M | $115.22M |
| Dividends paid | - | - | - | - | - |
Adicet Bio, Inc. reported operating cash flow of -$95.25M for fiscal year 2025. That is down 3.1% from -$92.38M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$10.98M (FY 2017) to -$95.25M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $75.25M | $111.31M | $236.00K | $41.51M | $242.69M | $303.00K |